Advertisement

Topics

Octapharma USA, Inc Company Profile

00:15 EST 12th December 2018 | BioPortfolio

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell-lines. Octapharma employs approximately 6,000 people worldwide to support the treatment of patients in over 100 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com, www.octagamus.net, www.octaplasus.com or www.wilateusa.com.


News Articles [10 Associated News Articles listed on BioPortfolio]

Octapharma AG Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175

Octapharma AG Strategy, SWOT and Corporate Finance ReportSummaryOctapharma AG Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report cover...

Octapharma AG Strategic SWOT Analysis Review [Report Updated: 25072018] Prices from USD $125

Octapharma AG Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT an...

Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies

Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorization to its new fibrinogen concentrate product fibryga® for the ...

Swissmedic approves fibryga to treat congenital and acquired fibrinogen deficiencies

This approval is an important achievement for the company and most importantly, represents major progress for patients and physicians. Octapharma board member Olaf Walter said: “The development of ...

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (r...

Octapharma AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummaryOctapharma AG Octapharma is a human protein manufacturer that focuses on developing and producing human proteins from human plasma and cell lines. The company treats patients worldwide with pro...

Octapharma AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryOctapharma AG Octapharma is a human protein manufacturer that focuses on developing and producing human proteins from human plasma and cell lines. The company treats patients worldwide with pro...

Octapharma AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27082018] Prices from USD $250

SummaryOctapharma AG Octapharma is a human protein manufacturer that focuses on developing and producing human proteins from human plasma and cell lines. The company treats patients worldwide with pro...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Albumin (human) [Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.]

These highlights do not include all the information needed to use ALBUMIN (HUMAN) 5% safely and effectively. See full prescribing information for ALBUMIN (HUMAN) 5%. ALBUMIN (HUMAN) 5% For intravenous...

Albumin (human) [Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.]

These highlights do not include all the information needed to use ALBUMIN (HUMAN) 20% safely and effectively. See full prescribing information for ALBUMIN (HUMAN) 20%. ALBUMIN (HUMAN) 20% For intraven...

Albumin (human) [Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.]

These highlights do not include all the information needed to use ALBUMIN (HUMAN) 25% safely and effectively. See full prescribing information for ALBUMIN (HUMAN) 25%. ALBUMIN (HUMAN) 25% For intraven...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.

To assess the safety and efficacy of an intravenous immunoglobulin (IVIG) 10% preparation (Panzyga; Octapharma AG, Lachen, Switzerland) in predominantly antibody-deficient children with primary immuno...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Patients with primary or secondary immunodeficiency disease who have developed adverse reactions to products available on the market such as Cuvitru® (Shire), Hizentra® (CSL Behring) or ...

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wila...

Companies [7 Associated Companies listed on BioPortfolio]

Octapharma AG

Octagam®10% is a liquid, 10% (100 mg/mL) immune globulin (human) solution for intravenous administration (IVIG) which is currently registered in European countries and expected...

Octapharma USA

Headquartered in Lachen, Switzerland, Octapharma is one of the largest plasma products manufacturers in the world and has been committed to patient care and medical innovation for over 25 years. Octap...

Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and huma...

Octapharma

Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality plasma derivatives.From its foun...

Octapharma USA, Inc

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovat...

More Information about "Octapharma USA, Inc" on BioPortfolio

We have published hundreds of Octapharma USA, Inc news stories on BioPortfolio along with dozens of Octapharma USA, Inc Clinical Trials and PubMed Articles about Octapharma USA, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Octapharma USA, Inc Companies in our database. You can also find out about relevant Octapharma USA, Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Corporate Database Quicklinks



Searches Linking to this Company Record